StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) stock

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)

Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –

Alnylam Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Alnylam Pharmaceuticals's total assets was $7.99B at Sep 30, 2026. For fiscal 2025 it was $4.97B, up 17.1% from the year before. Over ten years it grew 13.6% a year on average. The highest annual figure on record is $4.97B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.97B+17.1%
FY2024Dec 31, 2024$4.24B+10.7%
FY2023Dec 31, 2023$3.83B+8.0%
FY2022Dec 31, 2022$3.55B-2.7%
FY2021Dec 31, 2021$3.64B+6.9%
FY2020Dec 31, 2020$3.41B+42.2%
FY2019Dec 31, 2019$2.40B+52.1%
FY2018Dec 31, 2018$1.57B-21.1%
FY2017Dec 31, 2017$1.99B+58.0%
FY2016Dec 31, 2016$1.26B-8.9%
FY2015Dec 31, 2015$1.39B+28.4%
FY2014Dec 31, 2014$1.08B+156.7%
FY2013Dec 31, 2013$420.53M+46.3%
FY2012Dec 31, 2012$287.52M+2.0%
FY2011Dec 31, 2011$281.92M-28.3%
FY2010Dec 31, 2010$393.27M-18.3%
FY2009Dec 31, 2009$481.39M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$7.99B+64.8%
Q2 FY2026Jun 30, 2026$5.56B+21.7%
Q1 FY2026Mar 31, 2026$5.13B+21.7%
Q4 FY2025Dec 31, 2025$4.97B+17.1%
Q3 FY2025Sep 30, 2025$4.85B+15.4%
Q2 FY2025Jun 30, 2025$4.57B+13.9%
Q1 FY2025Mar 31, 2025$4.21B+10.2%
Q4 FY2024Dec 31, 2024$4.24B+10.7%
Q3 FY2024Sep 30, 2024$4.21B+9.5%
Q2 FY2024Jun 30, 2024$4.01B+17.8%
Q1 FY2024Mar 31, 2024$3.82B+12.7%
Q4 FY2023Dec 31, 2023$3.83B+8.0%
Q3 FY2023Sep 30, 2023$3.84B+8.6%
Q2 FY2023Jun 30, 2023$3.40B+2.2%
Q1 FY2023Mar 31, 2023$3.39B-1.2%
Q4 FY2022Dec 31, 2022$3.55B-2.7%
Q3 FY2022Sep 30, 2022$3.54B+1.8%
Q2 FY2022Jun 30, 2022$3.33B-5.1%
Q1 FY2022Mar 31, 2022$3.43B+5.5%
Q4 FY2021Dec 31, 2021$3.64B+6.9%
Q3 FY2021Sep 30, 2021$3.47B+5.0%
Q2 FY2021Jun 30, 2021$3.51B+4.0%
Q1 FY2021Mar 31, 2021$3.26B+42.8%
Q4 FY2020Dec 31, 2020$3.41B+42.2%
Q3 FY2020Sep 30, 2020$3.31B+30.1%
Q2 FY2020Jun 30, 2020$3.37B+24.2%
Q1 FY2020Mar 31, 2020$2.28B+13.2%
Q4 FY2019Dec 31, 2019$2.40B+52.1%
Q3 FY2019Sep 30, 2019$2.54B+51.7%
Q2 FY2019Jun 30, 2019$2.72B+51.8%
Q1 FY2019Mar 31, 2019$2.01B+4.7%
Q4 FY2018Dec 31, 2018$1.57B-21.1%
Q3 FY2018Sep 30, 2018$1.68B+23.4%
Q2 FY2018Jun 30, 2018$1.79B+24.8%
Q1 FY2018Mar 31, 2018$1.92B+69.6%
Q4 FY2017Dec 31, 2017$1.99B+58.0%
Q3 FY2017Sep 30, 2017$1.36B–
Q2 FY2017Jun 30, 2017$1.43B–
Q1 FY2017Mar 31, 2017$1.13B–
Q4 FY2016Dec 31, 2016$1.26B–

More Alnylam Pharmaceuticals figures

See a number that looks wrong?